← Leaderboards
William D Figg
Clinical Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Thalidomide”
- Walter John Curran · Thomas Jefferson University$26,641,549
- William G Kaelin · Dana-Farber Cancer Institute$9,761,992
- Patricia M Rodier · University Of Rochester$5,610,286
- Michele Pagano · New York University School Of Medicine$5,565,349
- Keith R. McCrae · Case Western Reserve University$5,447,978
- Peter Leif Bergsagel · Weill Medical College Of Cornell Univ$5,124,352
Research focus
ThalidomideAntineoplasticsPaclitaxelSuraminButyratesAngiogenesis InhibitorsHuman SubjectPatient Oriented ResearchPharmacokineticsPhenylacetatesNeoplasm /Cancer ChemotherapyTissue Inhibitor Of MetalloproteinasesHuman Therapy EvaluationDrug Screening /EvaluationPhenylcarboxylateClinical Trial Phase IProstate NeoplasmsKetoconazolePharmaceutical PreparationsImmunoconjugatesZidovudineDrug KineticsDrug MetabolismAndrogen Receptor
Grant awards (34)
Identify SNPs and Polymorphisms Involved in the Development of Prostate Cancer$355,712
Z01 · FY2007 · CA · contact PI
Development of Angiogenesis Inhibitors$355,712
Z01 · FY2007 · CA · contact PI
Clinical Pharmacogenetics$355,712
Z01 · FY2007 · CA · contact PI
Sample Processing and Analytical Methods Development for New Anticancer Agents$294,304
Z01 · FY2007 · CA · contact PI
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies$232,894
Z01 · FY2007 · CA · contact PI
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer Agents$232,894
Z01 · FY2007 · CA · contact PI
Development of Drugs That Target Prostate Cancer$171,486
Z01 · FY2007 · CA · contact PI
Identify SNPs and Polymorphisms Involved in the Developm$0
Z01 · FY2006 · BC · contact PI
Clinical Pharmacogenetics$0
Z01 · FY2006 · BC · contact PI
Development of Drugs That Target Prostate Cancer$0
Z01 · FY2006 · BC · contact PI
Development of Angiogenesis Inhibitors$0
Z01 · FY2006 · SC · contact PI
Development of Drugs That Target Prostate Cancer$0
Z01 · FY2005 · BC
Development of Angiogenesis Inhibitors$0
Z01 · FY2005 · SC
Clinical Pharmacology$0
Z01 · FY2005 · BC
Identify SNPs and Polymorphisms that are Important in th$0
Z01 · FY2005 · BC
Clinical Pharmacology$0
Z01 · FY2004 · BC
Identify SNPs and Polymorphisms that are Important in th$0
Z01 · FY2004 · BC
Development of Angiogenesis Inhibitors$0
Z01 · FY2004 · SC
Identify SNPs and Polymorphisms that are Important in th$0
Z01 · FY2003 · BC
Development of Angiogenesis Inhibitors$0
Z01 · FY2003 · SC
Clinical Pharmacology Principals in Developing Anticance$0
Z01 · FY2003 · SC
Development of Analytical Methods for New Anticancer and$0
Z01 · FY2003 · SC
Pharmacokinetic and Pharmacodynamic Modeling of Anticanc$0
Z01 · FY2003 · BC
Development of Drugs That Target Prostate Cancer$0
Z01 · FY2003 · BC
Development of Analytical Methods for New Anticancer and$0
Z01 · FY2002 · SC
Development of Angiogenesis Inhibitors$0
Z01 · FY2002 · SC
Using Clinical Pharmacology Principals in the Developmen$0
Z01 · FY2002 · SC
SNPs /Polymorphisms in Development of Prostate Cancer$0
Z01 · FY2002 · BC
Pharmacokinetic Models--Disposition of Anticancer Agents$0
Z01 · FY2001 · SC
Angiogenesis Inhibitor Development--Prostate Cacer Model$0
Z01 · FY2001 · SC
Analytical Method Develop.--Anticancer /Antiviral Agents$0
Z01 · FY2001 · SC
Development of Analytical Methods for New Anticancer and Antiviral Agents$0
Z01 · FY2000 · SC
Development of Angiogenesis Inhibitors using Prostate Cancer as a Tumor Model$0
Z01 · FY2000 · SC
Development of Pharmacokinetic Models to Characterize the Disposition of New Ant$0
Z01 · FY2000 · SC